ApprovalTrail

Approval · Notice of Compliance 36258 · 2025

DUTASTERIDE: Notice of Compliance 36258

Issued October 23, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
36258
Date
October 23, 2025
Company
Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Admin
Reason
Administrative: Licensing Agreement between two manufacturers
Canadian reference product
AVODART (Glaxosmithkline Inc)

Products in this notice

BrandDINStatus today
DUTASTERIDE02429012Marketed

Medicinal ingredients